These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33903060)

  • 21. Substitution of marijuana for opioids in a national survey of US adults.
    Ishida JH; Wong PO; Cohen BE; Vali M; Steigerwald S; Keyhani S
    PLoS One; 2019; 14(10):e0222577. PubMed ID: 31584957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Medical Marijuana Legalization on Opioid Use, Chronic Opioid Use, and High-risk Opioid Use.
    Shah A; Hayes CJ; Lakkad M; Martin BC
    J Gen Intern Med; 2019 Aug; 34(8):1419-1426. PubMed ID: 30684198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacists' training, perceived roles, and actions associated with dispensing controlled substance prescriptions.
    Fleming ML; Barner JC; Brown CM; Shepherd MD; Strassels SA; Novak S
    J Am Pharm Assoc (2003); 2014; 54(3):241-50. PubMed ID: 24816350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How does use of a prescription monitoring program change pharmacy practice?
    Green TC; Mann MR; Bowman SE; Zaller N; Soto X; Gadea J; Cordy C; Kelly P; Friedmann PD
    J Am Pharm Assoc (2003); 2013; 53(3):273-81. PubMed ID: 23699676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An opioid dispensing and misuse prevention algorithm for community pharmacy practice.
    Rickles NM; Huang AL; Gunther MB; Chan WJ
    Res Social Adm Pharm; 2019 Aug; 15(8):959-965. PubMed ID: 29525483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Community Pharmacists' Perspectives on Dispensing Medications With the Potential for Misuse, Diversion, and Intentional Overdose: Results of a Province-Wide Survey of Community Pharmacists in Canada.
    Leong C; Alessi-Severini S; Sareen J; Enns MW; Bolton J
    Subst Use Misuse; 2016 Nov; 51(13):1724-30. PubMed ID: 27487323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using the theory of planned behavior to investigate community pharmacists' beliefs regarding engaging patients about prescription drug misuse.
    Fleming ML; Bapat SS; Varisco TJ
    Res Social Adm Pharm; 2019 Aug; 15(8):992-999. PubMed ID: 30442574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opioid risk screening: Program evaluation from the community pharmacists' perspective.
    Frenzel O; Eukel H; Lothspeich E; Skoy E; Steig J; Strand M; Werremeyer A
    J Am Pharm Assoc (2003); 2022; 62(3):859-863.e1. PubMed ID: 34953730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Applying the capability, opportunity, motivation, and behavior model to identify opportunities to increase pharmacist comfort dispensing naloxone in Texas: A structural equation modeling approach.
    Varisco TJ; Downs CG; Rathburn KR; Fleming ML; Thornton JD
    Int J Drug Policy; 2020 Sep; 83():102827. PubMed ID: 32589581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
    Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
    Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Practice Patterns and Training Needs Among Physicians Certifying Patients for Medical Marijuana in Florida.
    Sajdeya R; Shavers A; Jean-Jacques J; Costales B; Jugl S; Crump C; Wang Y; Manfio L; Pipitone RN; Rosenthal MS; Winterstein AG; Cook RL
    J Prim Care Community Health; 2021; 12():21501327211042790. PubMed ID: 34452585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical decision making involving prescription drug monitoring programs: A factorial, vignette-based study among student pharmacists.
    Tata V; Varisco TJ; Du N; Nguyen J; Haghparast P; Thornton JD
    J Am Pharm Assoc (2003); 2021; 61(3):316-324. PubMed ID: 33579594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacists' role in opioid overdose: Kentucky pharmacists' willingness to participate in naloxone dispensing.
    Freeman PR; Goodin A; Troske S; Strahl A; Fallin A; Green TC
    J Am Pharm Assoc (2003); 2017; 57(2S):S28-S33. PubMed ID: 28139459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Connecticut Prescription Monitoring and Reporting System (CPMRS). How prescribers and pharmacists can help reduce prescription drug misuse and abuse.
    Conn Med; 2008 Aug; 72(7):439-40. PubMed ID: 18763674
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacists' knowledge of and attitudes toward opioid pain medications in relation to federal and state policies.
    Joranson DE; Gilson AM
    J Am Pharm Assoc (Wash); 2001; 41(2):213-20. PubMed ID: 11297334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacists' attitudes, knowledge, utilization, and outcomes involving prescription drug monitoring programs: A brief scoping review.
    Johnston K; Alley L; Novak K; Haverly S; Irwin A; Hartung D
    J Am Pharm Assoc (2003); 2018; 58(5):568-576. PubMed ID: 30030040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacists' attitudes toward dispensing naloxone and medications for opioid use disorder: A scoping review of the literature.
    Muzyk A; Smothers ZPW; Collins K; MacEachern M; Wu LT
    Subst Abus; 2019; 40(4):476-483. PubMed ID: 31418645
    [No Abstract]   [Full Text] [Related]  

  • 38. Prescription Drug Monitoring Programs and Pharmacist Orientation Toward Dispensing Controlled Substances.
    Fendrich M; Bryan JK; Hooyer K
    Subst Use Misuse; 2018 Jul; 53(8):1324-1330. PubMed ID: 29297725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prescription drug monitoring programs in community pharmacy: An exploration of pharmacist time requirements and labor cost.
    Upton C; Gernant SA; Rickles NM
    J Am Pharm Assoc (2003); 2020; 60(6):943-950. PubMed ID: 32792293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence.
    Raisch DW; Fudala PJ; Saxon AJ; Walsh R; Casadonte P; Ling W; Johnson BA; Malkerneker U; Ordorica P; Williford WO; Sather MR
    J Am Pharm Assoc (2003); 2005; 45(1):23-32. PubMed ID: 15730114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.